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Hepatitis C virus (HCV) infects an estimated more than 150 mil-
lion people and is a leading cause of liver disease worldwide. The
development of direct-acting antivirals (DAAs) will markedly
improve the outcome of antiviral treatment with cure of the
majority of treated patients. However, several hurdles remain
before HCV infection can be considered a menace of the past:
High treatment costs will most likely result in absent or limited
access in middle and low resource countries and will lead to
selective use even in wealthier countries. The limited efﬁcacy of
current HCV screening programs leads to a majority of cases
being undiagnosed or diagnosed at a late stage and DAAs will
not cure virus-induced end-stage liver disease such as hepatocel-
lular carcinoma. Certain patient subgroups may not respond or
not be eligible for DAA-based treatment strategies. Finally, rein-
fection remains possible, making control of HCV infection in peo-
ple with ongoing infection risk difﬁcult. The unmet medical needs
justify continued efforts to develop an effective vaccine, protect-
ing from chronic HCV infection as a mean to impact the epidemic
on a global scale. Recent progress in the understanding of virus–
host interactions provides new perspectives for vaccine develop-
ment, but many critical questions remain unanswered. In this
review, we focus on what is known about the immune correlates
of HCV control, highlight key mechanisms of viral evasion that
pose challenges for vaccine development and suggest areas of
further investigation that could enable a rational approach to
vaccine design. Within this context we also discuss insights fromJournal of Hepatology 20
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The arrival of powerful new direct-acting antivirals (DAA) will
dramatically change the care of patients chronically infected with
hepatitis C virus (HCV) [1]. Individuals who are aware of the
infection, have access to state of the art medical care and have
prescription coverage for these drugs can expect to be cured from
the infection in almost all cases – yet the question remains how
many of the more than 150 million people in the world, infected
with HCV, will fall into this group; so far the following key
challenges remain [1]:
First, high costs will limit access to drugs even in high
resource countries where it remains to be seen to what degree
the new treatments will reach key patient populations, especially
those with the highest risk proﬁles [2]. In countries with less
medical and ﬁnancial resources, some of which have the highest
incidence of HCV infection, the hurdles will even be higher [3].
Even with dramatically reduced prices for the new DAA therapies
that have recently been announced by the pharmaceutical indus-
tries for countries such as India and Egypt [3], it is far from clear
into how many successfully treated individuals this will
translate.
Second, in the absence of effective screening programs, HCV
infection is often diagnosed at a late stage or rarely diagnosed
at all (in low and middle income countries) and DAAs will not
cure already established liver disease such as hepatocellular
carcinoma.
Third, DAAs may have limitations in certain clinical scenarios
such as genotype 3 infection, advanced or decompensated liver
disease, transplantation, treatment experienced patients. Fur-
thermore, their use in children and pregnant women remains to
be determined [1,4].
Fourth, reinfection remains possible even after successful
curative therapy, especially in patient populations with contin-
ued exposure to HCV. Importantly, in this context, the United
States is experiencing a revitalized epidemic of intravenous14 vol. 61 j S34–S44
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heroin use, resulting in increasing number of new infections with
HCV [5]. Interrupting transmission networks through aggressive
treatment programs in this patient group may be possible [6],
but likely will be less efﬁcient than a prophylactic vaccine.
Given these challenges and despite the justiﬁed enthusiasm
about the new therapies available now and in the near future,
it is plausible that it will take an efﬁcient HCV vaccine to really
curb or even end this epidemic on a global scale [7]. Although
detailed studies, modelling the impact of a vaccine on HCV erad-
ication, are limited, previous data estimate that a prophylactic
HCV vaccine with 80% efﬁcacy would have a substantial impact
on the incidence of chronic HCV infection and would be highly
economically attractive [8,9].
Key Points
• An effective prophylactic HCV vaccine remains a 
critically important weapon to halt the global HCV 
epidemic
• It is unclear whether sterilizing immunity will be feasible, 
but protection from chronic infection would be as 
effective in preventing liver disease
• Both T cells and neutralizing antibodies are important 
for HCV control
• HCV viral diversity is the greatest challenge to an 
effective vaccine
• Testing HCV vaccines in clinical trials and learning from 
failure is key for advancing the field
How likely is an effective HCV vaccine?Fig. 1. Dichotomous natural outcome of HCV infection. After exposure to HCV,
patients display high levels of viraemia within days. Adaptive immune responses
(T cells and antibodies) develop after 6–10 weeks, in almost all patients, at which
time viraemia is at least partially controlled in most subjects and elevated liver
enzymes may appear. Maintenance of HCV-speciﬁc CD4 and CD8 T cell responses
and early development of neutralizing antibodies are associated with spontane-
ous eradication of HCV, usually within 24 weeks after infection (A). In contrast,
subjects developing chronic HCV infection quickly lose CD4 responses, followed
by a decline of the CD8 response and a delayed neutralizing antibody response
(B).There is reason to be optimistic about the possibility of an effec-
tive HCV vaccine. In contrast to most other chronic viral infec-
tions in humans, such as human immunodeﬁciency virus (HIV),
human herpes virus (HHV), cytomegalovirus (CMV) and
Epstein-Barr virus (EBV), HCV infection is spontaneously resolved
in a signiﬁcant number of infected individuals [10] (Fig. 1). In
addition, the 20–30% of patients with spontaneous control of
HCV are also much more likely to clear HCV after a second infec-
tion [11]. Furthermore, spontaneous clearance has been
described even in patients after long-term chronic infection
[12]. These observations suggest that with the right immune
response, chronic hepatitis C is preventable. Given that spontane-
ous resolution of HCV does not reliably prevent infection upon re-
exposure to the virus [11], the feasibility of a vaccine conferring
sterilizing immunity is questionable. While complete prevention
of infection would be preferable, a vaccine that reliable termi-
nates infection (Fig. 2) would have comparable impact, since
acute infection with HCV is usually asymptomatic with low mor-
bidity and almost zero mortality [10].
On the other hand, serious hurdles to an effective HCV vaccine
are evident and pose a major challenge. Foremost is the extreme
diversity of the virus that dwarfs even that of HIV. With less than
75% conservation at the amino acid level between each of the 7
major genotypes [13], a pan-genotypic vaccine would be a major
accomplishment. In addition, despite intense basic and clinical
immunological research in HCV and HIV infection, the key ele-
ments of a successful immune response remain ill-deﬁned.Journal of Hepatology 201Therefore, it is not exactly clear what kind of immune response
needs to be elicited by a vaccine in order to be effective. In the
end, these questions will most likely be answered by combining
additional translational research in acute and chronic HCV infec-
tion with clinical trials of vaccines in humans. These attempts at
vaccination might not be successful right away, but carefully
planned human trials and the analysis of the clinical, virological
and immunological features of vaccination and the dissection of
the response to HCV exposure or infection will contribute essen-
tial information to improve vaccine strategies.T cell responses and control of HCV infection
Evidence from chimpanzee and human studies support critical
roles for CD4 and CD8 T lymphocyte responses in the control of
primary and secondary HCV infection [14–28]. The strongest4 vol. 61 j S34–S44 S35
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Fig. 2. Two pathways to a prophylactic HCV vaccine. The ideal HCV vaccine
would induce sterilizing immunity, i.e. would completely prevent any HCV
infection. Such a vaccine would most likely be based on strongly cross-reactive
neutralizing antibodies to HCV (A). Since so far sterilizing immunity has appeared
elusive, many vaccine approaches have focused on preventing chronic infection,
and thus liver disease (B). This is based on the observation of natural immunity
against HCV and is expected to be primarily mediated by HCV-speciﬁc CD4 and
CD8 T cells, though recent data suggest that induction of neutralizing antibodies
could further enhance efﬁcacy.
Journal of Hepatology Update: Hepatitis Cevidence comes from T cell depletion experiments in the chim-
panzee model, where a lack of either CD4 or CD8 T cells during
exposure and early infection was associated with persistent vira-
emia [18,26]. The importance of CD4 and CD8 cells for the out-
come of HCV is further supported by human population studies
that identiﬁed strong associations between disease resolution
and certain human leukocyte antigen (HLA) class I and II alleles
in various ethnic populations [29–34].
Since in almost all cases spontaneous control of HCV is only
achieved in the acute phase of infection (ﬁrst 24 weeks, Fig. 1),
the main focus has been to study acute phase hepatitis to deter-
mine the relationship between HCV-speciﬁc T cell responses and
viral clearance. Interestingly, HCV-speciﬁc CD4 T helper- and CD8
cytotoxic T lymphocytes (CTL) responses develop quite late, being
ﬁrst detectable in the blood 6–10 weeks after infection in both
self-limited and chronically evolving hepatitis C [22–24,35,36],
despite high levels of HCV viraemia already detectable within a
week of exposure [15,37]. Whether the kinetics of the response,S36 Journal of Hepatology 201i.e. the duration until T cell responses appear, have an impact
on disease outcome is unclear and will be hard to ascertain in
human infection, given the challenges in identifying the speciﬁc
date of exposure. But if the timing of the response is important,
a vaccination that enables a much earlier T cell response to infec-
tion would provide a critical advantage to achieve viral control.
Other key determinants for the effectiveness of the T cell
response could be the breadth and magnitude of the response,
targeting of certain epitopes or viral regions, T cell functionality
and T cell regulation. In the next paragraphs we will lay out what
is currently known about T cell responses in spontaneously
resolving vs. chronic HCV infection and what still needs to be
deﬁned in the future.
CD4 T cells
The lack of HCV-speciﬁc CD4 T cell responses that proliferate
after antigenic stimulation in vitro is the hallmark of persistent
HCV infection [38–40]. In contrast, self-limited infection is char-
acterized by a broad range of HCV antigens inducing CD4 prolif-
eration in vitro and these assays remain positive for years and
even decades after the infection is cleared [39,40]. This is indica-
tive of a severe defect in HCV-speciﬁc CD4 T cells already at the
earliest stage of the host immune response. Apart from this spe-
ciﬁc defect, no conclusive differences have been observed so far
between HCV-speciﬁc CD4 T cells from different infection out-
comes in the initial phase of acute hepatitis. It was previously
assumed that the breadth and magnitude of the CD4 response
was directly linked to HCV clearance, since only individuals
who had spontaneously resolved HCV had detectable Th-1
responses, targeting a broad range of epitopes [39,41]. However,
a recent study from our laboratory has shown that most individ-
uals progressing to chronic infection develop CD4-responses
against HCV antigens with similar breadth and magnitude as
those with self-limited infection during the earliest phase of
the T cell response [42]. Only with the establishment of persistent
viraemia are additional defects observed beyond the lack of CD4
T cell proliferation, the most important being the physical dele-
tion of HCV speciﬁc CD4 T cells from the blood. Thus, a key fea-
ture of a successful immune response against HCV is the
maintenance of functional virus speciﬁc CD4 T cell responses in
the face of ongoing viral replication. Whether such responses
should preferably target certain epitopes or viral regions is not
known, as previous studies were unable to identify immunogenic
regions associated with distinct outcomes [42].
Another unanswered question is whether the phenotype of
the CD4 T cell response, elicited by a vaccine, is relevant. Only
recently have we begun to fully appreciate the heterogeneity of
the CD4 T cell response, with Th1, Th2, Th17, Th22, T follicular
helper and T regulatory cells being described [43], and how these
different CD4 T cell populations orchestrate the immune
response in very distinct ways. In this context it needs to be
remembered that most studies on the CD4 T cell response in
the aforementioned studies in HCV infection were performed
by functional tests skewed to detect Th1 responses, potentially
missing the contribution of other Th subsets to disease resolution
or HCV persistence. Extending our viewpoint, Kared et al. recently
reported that the expansion of Th17- HCV-speciﬁc CD4 T cells,
characterized as CD161hiCCR6+CD26+ and producing IL-17A and
IL-21, was associated with disease resolution [44]. In contrast,
reduced frequencies of IL-21 producing HCV-speciﬁc CD4 T cells4 vol. 61 j S34–S44
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combined with exhaustion and reduced proliferation of HCV-spe-
ciﬁc CD8 T cells were observed in viral persistence. The reduction
of IL-21 producing virus-speciﬁc CD4 cells in chronically evolving
infection appeared to be through Gal-9 expressing regulatory T
cells that activate TIM-3 on HCV-speciﬁc CD4 T cells [44]. Defects
were compensated in culture with supplementation of IL-21 that
promoted cell proliferation, as well as cell survival and the inhi-
bition of exhaustion of HCV-speciﬁc CD8 T cells. Another interest-
ing observation was contributed by Rowan et al. who have
suggested a possible role for Th-17 cells in the eradication of
HCV [45], although the production of IL-17 could be suppressed
by IL-10 and transforming growth factor beta (TGF-b), excreted
by monocytes in response to NS4 protein [46]. Besides these
studies, our understanding of the role of different CD4 T cell pop-
ulations in HCV, as well as in other acute and chronic viral infec-
tions, remains rather limited and warrants more detailed
research.
Based on our current knowledge, the aim for a vaccine is to
induce a broadly directed CD4 response against HCV that
responds quickly and lastingly in the face of a viral challenge
(Fig. 2). Whether it is necessary to ﬁne-tune that response, for
example in terms of the functionality or phenotype of the
induced CD4 T cells, is currently an open question.
CD8 T cells
HCV-speciﬁc CD8 T cells have higher frequencies compared to
CD4 T cell responses and direct visualization and phenotyping
of CD8 T cells using HLA multimers is technically much easier;
thus, many more studies have been performed on the early CD8
response than on the CD4 response in HCV infection. Despite
the plethora of studies on CD8 T cells, it is still not entirely clear
what kind of CD8 T cell response is required to achieve full con-
trol of HCV. Again, as with CD4 responses, vigorous and broadly
directed CD8 responses were observed in self-limited disease
[17,28], but if individuals were studied within the initial
6 months of HCV infection, similarly strong CD8 responses could
be seen in patients with a chronic course of infection [22]. What
we understand better, compared to the CD4 responses, are the
different mechanisms that render the HCV-speciﬁc CD8 T cell
response debilitated and unable to control the virus throughout
the progression to persistent viraemia.Table 1. Mechanisms of escape from T cell responses.
Escape route Mechanism 
Viral escape 
mutations 
HCV genetic variability (based on high transcription erro
proof-reading function of the viral polymerase) leads to e
variants that are not recognized by the existing T cell res
Frequently observed in response to CD8 T cells; escape
responses is less studied but seems rare
T cell 
exhaustion 
(intrinsic) 
Activation of various T cell inhibitory pathways (e.g., PD-
leads to viral exhaustion. Co-expression/activation of mu
leads to more severe exhaustion. Better examined for C
operative on CD4 T cells
T cell 
exhaustion 
(extrinsic)  
T cell regulatory cytokines (e.g., IL-10) and regulatory ce
CD4 Tregs) inhibit T cell function. Complexity and releva
interactions not fully understood
Journal of Hepatology 201Generally, at least two pathways are involved in viral evasion
from the CD8 response in chronic hepatitis C (Table 1). One is the
emergence of HCV variants that carry amino acid substitutions in
or around targeted CD8 epitopes that are associated with a lack of
recognition by epitope-speciﬁc CD8 T cells. CD8 T cell-mediated
viral escape occurs already during acute infection [47] and once
persistent viraemia is fully established, up to 50% or more of all
targeted CD8 epitopes can be mutated, depending on the cohort
[48–50]. These mutations typically come at a cost for the virus,
since often the escape variants show less replicative ﬁtness than
the original infecting virus [51,52]. Notably, carriers of the HLA
class I alleles B⁄27 and B⁄57 have a higher likelihood of clearing
HCV [53,54] and this has been associated with CD8 responses
against conserved epitopes within the non-structural protein
5B, with escape mutations within these epitopes resulting in a
profound viral ﬁtness cost [54–56]. In some cases, the virus
evolved even further, with additional mutations that compensate
for the initial loss of viral ﬁtness [52]. However, this multi-step
process requires time, especially when viral replication is some-
what diminished, which might explain why targeting certain epi-
topes confers a higher likelihood of viral control. Besides viral
ﬁtness, other factors such as T cell receptor (TCR) breadth, diver-
sity, functional avidity, and lack of CD4 T cell helper cells may
also play a role in determining the emergence of viral escape
mutations. Whether any of these factors are actually decisive in
allowing the virus to escape and thus, are primarily the cause
for viral persistence, or whether viral escape mutations are just
a consequence of other factors allowing viral persistence with
continuous high HCV replication rates is unknown. But with
regards to vaccine development, it is important to keep in mind
that certain qualities of the vaccine-induced CD8 response might
inﬂuence the likelihood of viral escape.
The other major mechanism, impeding effectiveness of the
HCV-speciﬁc CD8 T cell response in chronic infection, is T cell
exhaustion, which is characterized by an increasing failure of T
cells to exert their effector functions and at its ﬁnal step by phys-
ical deletion of virus-speciﬁc T cell populations [57,58]. Growing
evidence suggests that intrinsic regulatory pathways (such as
regulation through T cell inhibitory receptors) as well as extrinsic
regulatory pathways (such as immunoregulatory cytokines or
regulatory T cells) contribute to T cell exhaustion. In terms
of intrinsic regulatory pathways, it has been shown that[Ref.]
r rates due to lack of 
mergence of viral 
ponse.
 from CD4 
Timm J. et al., J Exp Med 2004
Cox A. L. et al., J Exp Med 2005
Kuntzen T. et al., J Virol 2007
Erickson A.L. et al., Immunity 2001
Fuller M.J. et al., Hepatology 2010 
1, CTLA4, TIM-3) 
ltiple receptors 
D8 T cells, but also 
Urbani S. et al., J Virol 2006
Kasprowicz V. et al., J Virol 2008
Bengsch B. et al., PLoS Pathog 2010
McMahan R.H. et al., J Clin Invest 2010 
Kroy D. et al., Gastroenterology 2014 
lls (e.g. FoxP3+ 
nce of these 
Accapezzato D. et al., J Clin Invest 2004
Sugimoto K. et al., Hepatology 2003 
Rushbrook S.M. et al., J Virol 2005
Kared H. et al., PLoS Pathog 2013
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virus-speciﬁc CD8 T cells in chronic infection may simultaneous
express different inhibitory receptors such as PD-1, CD160,
CTLA-4, TIM-3, 2B4, and KLRG1 [59]. The number of receptors
simultaneously expressed by a CD8 T cell seems to determine
the severity of T cell dysfunction [59] and the extent to which
the dysfunction is reversible. However, the relationship between
expression of inhibitory receptors and T cell exhaustion is not
straightforward, since during the early immune response T cells
typically express high levels of T cell inhibitory receptors, espe-
cially PD-1 [60], and this is observed even in subjects who spon-
taneously control HCV [61], or after immunization with the
highly efﬁcacious yellow fever vaccine [62]. Continued stimula-
tion with antigen drives higher levels of inhibitory receptor
expression and exhaustion in chronic infection [63]; but the
sweet spot for the perfect equilibrium between the physiological
role of these pathways, in preventing an overshooting immune
response that could result in immune–mediated disease, and
their potential contribution to T cell failure, has yet to be deﬁned.
Similar questions remain for extrinsic regulatory pathways, for
example IL-10 producing T cells or CD4+Foxp3+ regulatory T cells,
that have been suggested to expand in blood and liver during
chronic infection and are thought to contribute to HCV-speciﬁc
CD8 T cell exhaustion [41,64–68].
Overall, for the vaccine to be effective against HCV persis-
tence, there is little doubt that robust and broad T cell responses
are essential in an immune response to HCV (Fig. 2). However,
more work is needed to better deﬁne functional and phenotypic
properties of T cell responses that are associated with disease res-
olution, so that we could harness this information to ensure a
vaccine-induced response that is effective, long-lasting and resis-
tant to HCV-mediated immune evasion.Impact of neutralizing antibodies for prevention and control
of HCV infection
Neutralizing antibody (nAb) responses are critical components of
the host defence during viral infections and are recognized as a
key element in the protective immune response against infection
elicited by many prophylactic vaccines [69,70]. While their
potential role in preventing chronic infections with hypervariable
viruses such as HIV or HCV has been less clear, recent studies in
chimpanzees and clinical cohorts as well as mechanistic studies
in HCV cell culture and small animal models have revitalized
interest in the role of nAbs for protection against chronic HCV
infection.
Neutralizing antibodies and control of HCV infection in clinical
cohorts
Several studies have investigated the role of antibodies in the
control of HCV infection. Whereas viral clearance can occur in
the absence of nAbs in humans and chimpanzees [71], several
studies have demonstrated that nAbs may have an important role
in controlling infection. Pestka et al. studied the role of nAbs dur-
ing acute HCV infection [72]. The follow-up over 17 years in a
cohort of women accidentally infected by the same HCV strain
reveals a strong correlation between viral clearance and the rapid
induction of nAbs during the acute phase of HCV infection [72].
These conclusions were recently supported by Osburn et al.
who observed more rapidly developing broad humoral responsesS38 Journal of Hepatology 201in patients spontaneously clearing HCV infection [73]. Interest-
ingly, in a well-characterized patient with established chronic
HCV infection who later eliminated HCV spontaneously, clear-
ance also correlated with the appearance of nAbs [12].
Further support for the contribution of nAbs in the control of
HCV comes from studies in frequently exposed people who inject
drugs intravenously. Osburn et al. observed an increased rate of
viral clearance after HCV re-exposure compared to primary infec-
tion (83% clearance after re-exposure vs. 25% during primary
infection) [74]. Importantly, whereas cross-reactive nAbs are
rarely present in the sera of patients who develop chronic HCV
infection, they are detected in 60% of the subjects who cleared
the secondary infection [74]. The potential capacity of nAbs to
prevent HCV infection is also supported by observations in liver
transplantation with liver graft infection. A retrospective study
revealed that treatment of HCV-infected patients by hepatitis B
immunoglobulins (HBIG), hypothesized to incidentally contain
anti-HCV antibodies, during liver transplantation (LT) decreased
HCV recurrence [75]. Interestingly, HCV-negative patients under-
going LT, treated by the same anti-HCV contaminated HBIG and
exposed to HCV, presented a lower frequency of HCV acquired
infection [75]. These observations indicate that nAbs may protect
against HCV infection, especially in the context of LT where viral
evasion from nAbs has been described as a key feature of liver
graft infection [76,77].
Overall there is compelling clinical evidence that nAbs, target-
ing HCV, are contributing to both viral clearance during early
infection and protection against de novo HCV infection. These
observations support the concept that the development of an
effective HCV vaccine should include the induction of broadly
cross-neutralizing antibodies (Fig. 2).
Mechanisms of viral evasion from host neutralizing antibodies
The efﬁcacy of HCV nAb and also the design of an efﬁcient vac-
cine are greatly impacted by the considerable capacity of HCV
to alter its sequence and thus to escape humoral and cellular
immune responses. Notably, nAbs are mainly blocking viral entry
by targeting the HCV envelope glycoproteins (GPs) E1 and E2 and
their interaction with host entry factors. However, multiple
mechanisms enable the virus to persist in the presence of neu-
tralizing antibodies and evade virus-neutralization (Table 2).
HCV circulates in patients as a pool of variants, genetically dis-
tinct and continuously evolving. Even during established chronic
infection, the virus continues to respond to immune pressure
through the selection of mutants that are not neutralized by cir-
culating nAbs [78]. A similar observation has been made in acute
liver graft infection, where predominantly such viral escape vari-
ants infect the liver graft [76].
HCV can escape neutralization through single point mutations
such as modiﬁcations of glycosylation sites [79,80]. The virus can
also disseminate using cell-to-cell transmission, thus avoiding
the extracellular compartment with its presence of nAbs.
[81,82]. In addition HCV utilizes host-speciﬁc factors to escape
nAbs. Fofana et al. also demonstrated that mutations in the GP
E2, from a variant selected during LT, conferred viral escape to
humoral responses by altering the use of the T cell receptor
CD81 [77]. Escape through altered use of the scavenger receptor
B1 has also been described [83]. HCV circulates in the blood in
association with triglyceride-rich lipoproteins (TRL) and low-
density lipoproteins (LDL) forming hybrid lipoviral particles4 vol. 61 j S34–S44
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Table 2. Mechanisms of evasion from antibody responses.
Escape route Mechanism [Ref.]
Viral diversity 
 environment and evasion from humoral responses
Dowd K.A. et al., Gastroenterology 2009 
Gal-Tanamy M. et al., Proc Natl Acad Sci 2008
Von Hahn T. et al., Gastroenterology 2007
Liu L. et al., Hepatology 2012
Ray S.C. et al., J Exp Med 2005 
Glycosylation 
of structural 
proteins 
Numerous glycans present at the surface of HCV GPs reduce access of 
nAbs to their epitopes 
Helle F. et al., J Virol 2007
Helle F. et al., J Virol 2010 
Cell-to-cell 
transmission 
HCV can disseminate directly using cell-to-cell transmission thus avoiding 
extracellular exposure to antibodies 
Timpe J.M. et al., Hepatology 2008
Brimacombe C.L. et al., J Virol 2011 
Xiao F. et al.,  PLoS Pathogens 2014
Association 
with 
lipoproteins 
HCV association with lipoproteins reduces viral sensitivity to nAbs by 
obscuring epitope to which antibodies bind 
André P. et al., J Virol 2002
Grove J. et al., J Virol 2008 
Induction of 
interfering 
antibodies 
interfering antibodies produced incidentally by the host 
Zhang P. et al., Proc Natl Acad Sci 2009 
Mutations 
altering entry 
factor use 
Mutations in the GPs confer viral escape to humoral responses by altering 
the use of the host cell receptors 
Fofana I. et al., Gastroenterology 2012 
HCV genetic variability allows the virus its adaptation to the host
Efficient neutralization of HCV by nAbs can be disturbed by the presence of
GP, envelope glycoproteins; nAbs, neutralizing antibodies.
JOURNAL OF HEPATOLOGY(LVP) [84]. By obscuring epitopes to which nAbs bind, these asso-
ciations may reduce the sensitivity of particles to antibody med-
iated neutralization and facilitate HCV persistence [83,84].
Finally, the immune system itself may incidentally enable HCV
persistence by the presence of antibodies capable to interfere
and block activity of nAbs [85,86].
Despite these challenges, broadly cross-neutralizing monoclo-
nal antibodies, directed against the E2 envelope glycoprotein that
can efﬁciently block HCV infection of various genotypes, have
been isolated from HCV-chronically infected patients or immu-
nized animals [87–89]. The characterization of these antibodies
also led to a better understanding of the GPs structure, which is
essential for deﬁning epitopes that promise to be effective immu-
nogens. Just recently Kong et al. have successfully characterized
the structure of the E2 core by obtaining a crystal of the E2 core
in association with the fragment antigen-binding region (FAb) of
a high avidity binding human monoclonal antibody [90]. Besides
revealing a globular structure of E2 that has also been afﬁrmed by
others [91], this study identiﬁed an essential and conserved epi-
tope on E2 that may be used for vaccine design [90].
Undoubtedly, the effectiveness of HCV to evade host immune
responses remains a major challenge for the development of a
protective vaccine. However, recent progress in the better under-
standing of both HCV structure and immunology have renewed
the hope that a sterilizing, antibody-based vaccine for HCV might
be a possibility.Prophylactic and therapeutic vaccine approaches in
chimpanzees and humans
Within the last two decades, several prophylactic and therapeutic
vaccine candidates based on diverse strategies (induction of anti-
body vs. T cell responses), using different delivery approachesJournal of Hepatology 201(recombinant proteins, peptides, DNA, virus-like particles, viral
vectors, yeast) and targeting different regions of the HCV poly-
protein have been developed in preclinical animal models includ-
ing rodents and chimpanzees. Several candidates were also
evaluated in clinical trials in healthy volunteers or in HCV
infected patients (Table 3). In this overview we will focus on
the more advanced vaccine candidates, for which data in either
chimpanzees or humans are publicly available.
Prophylactic vaccine candidates
A prophylactic vaccine remains the most effective approach to
decisively impact an epidemic or even eradicate a pathogen glob-
ally. In the case of HCV infection, such a vaccine would ideally
confer sterilizing immunity, but the reliable prevention of
chronic infection would be an acceptable alternative, since
almost all the sequelae of HCV infection result later during persis-
tent infection.
Prevention of HCV chronicity is the aim of the prophylactic T
cell vaccine approach that is currently the furthest in clinical
development and that has shown by far the strongest immunoge-
nicity with regard to eliciting T cell responses. The original idea
was to use the excellent immunogenicity of adenoviruses, and
through selection of adenovirus serotypes that rarely infect
humans (human adenovirus 6, Ad6; chimpanzees adenovirus 3,
ChAd3) avoid interference with pre-existing nAbs. Folgori et al.
tested the efﬁcacy of two immunizations by MRKAd6, coding
for HCV NS proteins, followed by boost injections of
MRKAd24NSmut and later a plasmid DNA encoding NS proteins
in chimpanzees [92]. The vaccination induced vigorous and
broadly directed T cell responses, with a further signiﬁcant
enhancement of CD4 and CD8 T cell responses after MRKAd24NS-
mut and DNA boosts. After HCV challenge, all animals became
infected but HCV replication was contained (100 times lower4 vol. 61 j S34–S44 S39
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Table 3. Examples for vaccine approaches hat have been investigated in preclinical studies in chimpanzees or clinical trials in humans.
Approach Prophylactic/
therapeutic 
Immunogen-adjuvant Stage of 
development 
Current status [Ref.] 
Peptides/
proteins 
Prophylactic E1E2 Chimpanzees Published Choo Q.L. et al., Proc Natl Acad 
Sci USA 1994;  
Meunier J.C. et al., J Infect Dis 2011 
Core-iscomatrix™ Phase I
(30 volunteers)
Published Drane D. et al., Hum Vaccines 2009 
E1E2-MF59C.1 Phase I
(60 volunteers) 
Published Frey S.E. et al., Vaccine 2010; 
Stamataki Z. et al., J Infect Dis 2011 
E1E2 Phase I
(50 volunteers) 
Recruiting NCT01718834 
Therapeutic IC41-
poly-L-arginine 
Phase I/II
(128 volunteers/60 patients) 
Published Firbas C. et al., Vaccine 2006; 
Klade C.S. et al., Gastroenterology 
2008; Schlaphoff V. et al., 
Vaccine 2007
IC41-
imiquimod 
Phase II
(50 patients) 
Published Klade C.S. et al., Vaccine 2012
IC41 Phase II
(71 patients) 
Completed NCT00601770 
E1E2
(Cenv3) 
Phase II
(28 patients) 
Published El-Awady M.K. et al., Vaccine 2013   
HCV-LP Prophylactic Core E1E2 Chimpanzees Published Elmowalid G.A. et al., 
Proc Natl Acad Sci USA 2007  
DNA vector Prophylactic E2 Chimpanzees Published Forns X. et al., Hepatology 2000  
Therapeutic Core E1E2
(CIGB-230) 
Phase II
(15 patients)
Published Alvarez-Lajonchere L. et al., 
J Viral Hepat 2009  
NS3/4A 
(ChronVac-C) 
Phase II Recruiting NCT01335711 
Viral vector Prophylactic Ad6NSmut
DNA-NSmut 
Chimpanzees Published Folgori A. et al., Nat Med 2006  
Ad6NSmut
ChAd3NSmut
Phase I
(40 volunteers) 
Published Barnes E. et al., 
Sci Transl Med 2012   
AdCh3NSmut
MVA-NSmut
Phase I/II
(68 + 276 IDU) 
Recruiting NCT01436357 
Therapeutic AdCh3NSmut
MVA-NSmut
Phase I
(19 volunteers 
/14 patients) 
Recruiting NCT01296451 
TG4040 Phase I
(15 patients) 
Published Habersetzer F. et al., 
Gastroenterology 2011  
TG4040 + SOC Phase II
(153 patients) 
Published DiBisceglie A.M. et al., 
Gastroenterology 2014  
Ad6NSmut
ChAd3NSmut 
Phase I
(32 patients) 
Completed NCT01094873 
Ad6NSmut
MVA-Nsmut + SOC 
Phase I
(9 patients) 
Completed NCT01701336 
SOC, standard of care; HCV-LP, HCV-like particles.
Journal of Hepatology Update: Hepatitis Cviral loads) and 4/5 immunized chimpanzees cleared the virus
with signiﬁcantly shorter duration of viraemia compared to
unvaccinated animals. No increase in liver enzymes was observed
in any of the immunized animals [92]. Based on these results, a
phase I clinical trial was initiated with 40 healthy individuals,
evaluating the safety and efﬁcacy of immunization using a single
or double prime of Ad6NSmut vector, followed by a boost with
the ChAd3NSmut vector, or by using the inverse vaccination
sequence [93]. Both vectors induced speciﬁc and broad cross-
reactive T cell responses with cytokine secretion in the vaccinees.
Importantly, a functional and proliferating long-term T cell pop-
ulation was still detected after one year [93]. Two additional clin-
ical trials (phase I and phase I/II) are currently recruitingS40 Journal of Hepatology 201participants (NCT01296451, NCT01436357) with a further modi-
ﬁed approach, employing ChAd3NSmut followed by a modiﬁed
vaccinia Ankara (MVA) virus, the latter being selected for its efﬁ-
cacy in boosting T cell responses [94]. Clinical trial NCT01436357
is the ﬁrst trial to enrol at risk subjects (injecting drug users) and
will therefore have the capacity to evaluate vaccine efﬁcacy in
humans.
A very distinct approach, employing recombinant proteins
and targeting the HCV envelope, was based on the observation
that recombinant E1E2 proteins induced cross-nAbs in chimpan-
zees and seemed to at least partially protect them from HCV
infection [95,96]. A phase I clinical trial in 60 healthy volunteers
immunized with different doses of HCV E1E2 proteins (genotype4 vol. 61 j S34–S44
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1a) combined with MF59C.1 adjuvant [97] demonstrated good
safety of the vaccine and the induction of envelope-speciﬁc CD4
T cell and humoral responses [97]. The neutralization capacity
of Abs elicited by the vaccine was tested on HCV pseudoparticles.
Evidence for antibodies with neutralizing activities was detected
in a signiﬁcant number but not in all subjects [97]. An in depth
analysis of sera from patients of the same cohort showed that
all sera neutralized against in vitro infection with heterologous
1a, 1b, and 2a strains [98].
HCV core protein adjuvanted with the ISCOMATRIX™ (that is
known for its capacity to increase CD4 and CD8 T cell responses)
has also been tested in a phase I clinical trial on 30 healthy indi-
viduals [99]. Speciﬁc humoral responses (Abs titres >10) were
detected in all except one subject (23/24) whereas CD8 T cell
responses were detected only in 2/8 subjects who received the
highest dose [99].
The use of recombinant HCV proteins in vaccine design in the
previously discussed vaccine approaches present some disadvan-
tages especially concerning the correct folding of the proteins and
the processes of production [100–102]. To overcome these limita-
tions, Elmowalid et al. developed virus-like particles (VLPs),
expressing HCV structural proteins, as a potential vaccine candi-
date [101]. In this study, performed on chimpanzees, all animals
immunized with HCV-like particles (HCV-LPs) developed speciﬁc
CD4 and CD8 T cell responses with cytokine production. Upon
HCV challenge, all four animals became infected but after ten
weeks three of them cleared the virus and just one continued
to have intermittent viraemia with low HCV RNA titres. After vac-
cination an increase in the magnitude of peripheral and intrahe-
patic T cell and proliferative responses against the HCV structural
proteins was observed [101]. A clinical trial in humans has not
yet been reported using this approach. Other concepts based on
subviral/virus-like or native particles are currently being pursued
using recombinant hepatitis B virus (HBV) subviral particles
expressing HCV envelope epitopes [102], recombinant cell
culture-derived HCV (HCVcc) [103] or retroviral pseudotypes
expressing HCV envelope glycoproteins [100].
Therapeutic vaccine candidates
The recent licensing of DAAs is rapidly changing the care of
chronically HCV infected patients, including difﬁcult-to-treat
populations, such as patients with liver cirrhosis or HIV coinfec-
tion, and it is expected that the vast majority of patients on treat-
ment will achieve sustained virologic response (SVR) [1]. Thus,
the impact of therapeutic vaccines in the arsenal of antiviral
treatment is most likely limited and most pharmaceutical com-
panies have halted the clinical development of therapeutic vac-
cines. For this reason, but also because of the rather limited
efﬁcacy in published studies, we will only brieﬂy summarize
some well-characterized concepts for immunotherapeutic
approaches as examples. Despite the so far disappointing results,
important lessons might be learned from immunotherapeutic tri-
als in chronic hepatitis C, especially for new approaches to
attempt immunotherapeutic control of chronic HBV infection.
A strong indication of the difﬁculties in using therapeutic vac-
cines as monotherapy for chronic HCV infection comes from a
trial using the vaccine approach based on chimpanzee adenovi-
ruses, expressing all HCV NS proteins, already described as a pro-
phylactic vaccine above. While vaccination in healthy volunteers
induced extremely broad and vigorous T cell responses [93], thisJournal of Hepatology 201approach resulted in no signiﬁcant changes in HCV viraemia
when administered in chronically infected patients and only
caused a boost of some T cell responses [104]. Importantly,
sequencing of the patients’ viruses revealed that only the T cell
responses that did not target the autologous circulating virus
were preferentially boosted after vaccination [104]. This supports
the general immunogenicity of the vaccine, but also highlights
the challenge of invigorating exhausted T cell responses that con-
tinue to recognize the circulating virus, without the addition of
antiviral therapy.
Two concepts which have been studied in detail in clinical tri-
als are T cell vaccines using peptides and recombinant poxvirus-
es. IC41 is a peptide vaccine, containing ﬁve synthetic peptides
from core, NS3 and NS4 proteins that correspond to conserved
HLA-A2 restricted CD8 and promiscuous CD4 epitopes, together
with poly-L arginine as an adjuvant. Phase I and phase II clinical
trials demonstrated that the approach is safe and well-tolerated,
though the induced T cell responses were relatively modest,
[105–107], especially when compared to responses, induced by
the viral vectors described above. No signiﬁcant changes in HCV
RNA were observed when patients with chronic HCV infection
were vaccinated [106]. IC41 was also supplemented with
imiquimod (a TLR7 agonist) and while there was some reduction
of viraemia after 16 weeks, there was no signiﬁcant correlation
between HCV levels and T cell immune responses [108]. Another
phase II clinical trial, investigating HCV virological responses
following biweekly immunization with IC41, is currently ongoing
(NCT00601770).
One of the most intensively studied concepts in patients is the
use of recombinant poxviruses, expressing HCV proteins contain-
ing immunodominant epitopes. TG4040 is a recombinant poxvi-
rus vaccine that expresses the hepatitis C virus (HCV) proteins
NS3, NS4, and NS5B. In an open-label, dose-escalating study in
patients with mild chronic hepatitis C (CHC), the viral-vector-
based vaccine TG4040 had a good safety proﬁle, but induced
weak HCV-speciﬁc cellular immune responses and had no sus-
tained effect on the viral load [109].
Several important lessons should be drawn from these stud-
ies: The ﬁrst is that new therapeutic vaccines need to be tested
in healthy individuals ﬁrst and not just in patients with chronic
HCV infection. Otherwise one cannot discriminate whether a vac-
cine is just not sufﬁciently immunogenic or whether the severe
exhaustion of T cells in chronic infection prevented a measurable
impact on the T cell response by an otherwise immunogenic
agent. Second, when increased immune responses are observed
after vaccination in chronic infection, it needs to be tested
whether these responses target the circulating virus in the indi-
vidual patient. Boosting T cells that are not exhausted, due to
not seeing the antigen, is easier to achieve but will have no
impact on viral replication, since they have no target in the
infecting viral strain. Finally, apart from the selection of the best
vaccine vector, the question of the right antigen remains open
and relevant. The use of a large part of the HCV genome will prob-
ably be the best to include in a HCV vaccine, given the typically
broad T cell response that is associated with spontaneous resolu-
tion of infection and that most likely limits the ability of the virus
to evade the immune response. However, antigens need to be
carefully chosen, allowing to optimize and broaden the immune
response while avoiding potentially detrimental effects, such as
peptide competition or the dominance of responses with limited
efﬁcacy.4 vol. 61 j S34–S44 S41
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Conclusions
Despite the recent dramatic progress in antiviral therapies for
chronic HCV infection, a prophylactic HCV vaccine remains an
extremely desirable asset in order to control the HCV epidemic
in all populations and in all regions of the world. Recent advances
in vaccine design have ﬁnally led to vaccination approaches that
reliable induce robust CD4 and CD8 T cell responses, similar to
what is observed in acute HCV infection. Through ongoing clinical
trials in persons at high risk for HCV infection, we should soon
ﬁnd out whether the pre-existence of broadly directed and vigor-
ous T cell responses is sufﬁcient to reliably prevent chronic HCV
infection, and, if protection can be achieved, whether it extends
signiﬁcantly beyond the HCV genotype from which the vaccine
was derived. The recent structural characterization of the interac-
tion of cross-neutralizing antibodies with the viral envelope gly-
coprotein E2 as well as understanding of the molecular
mechanisms of viral evasion from neutralizing antibodies, has
stimulated new concepts for the rational design of B cell vaccines.
Thus, in the meantime it seems prudent to further investigate
how neutralizing antibodies can contribute to HCV clearance or
even establish sterilizing immunity, how immunity can be broad-
ened to cover as many HCV strains as possible, and what kind of T
cell response proﬁle is most strongly associated with efﬁcient
control of HCV. Finally, since the chimpanzee model is no longer
available in the US and Europe, novel and innovative approaches
to assess the efﬁcacy and safety of future vaccine candidates are
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